µ²ºc¦¡ |
|
Pembrolizumab¬O¤@ºØ·½¦Û¤HÃþªº³æ®è§ÜÅé¡A¥iªýÂ_PD-1»P¨ä°tÅé(PD-L1»PPD-L2)¤§¶¡ªº¥æ¤¬§@¥Î¡CPembrolizumab¬O¤@ºØIgG4ƒÛ§K¬Ì²y³J¥Õ¡A¤À¤l¶q¬ù¬°149 kDa¡C KEYTRUDA¬°µLµß¡B¤£§t¨¾»G¾¯¡B¥Õ¦â¦Ü¦Ç¥Õ¦âªº§Ná°®À꯻¾¯¡A²±¸Ë©ó³æ¦¸¨Ï¥Î«¬¤p²~¤¤¡C
|
UpToDate |
UpToDate ³sµ²
|
ÃIJz§@¥Î |
|
PD-1°tÅé(PD-L1»PPD-L2)»PT²ÓM¤WªºPD-1µ²¦X·|§í¨îT²ÓM¼W¥Í§@¥Î¤Î²ÓM¿E¯À¥Í¦¨§@¥Î¡C¦b¬Y¨Ç¸~½F¤¤·|¥X²{PD-1°tÅé¼W¥[ªº²{¶H¡A¦Ó³z¹L¦¹¸ô®|¶Ç»¼°T®§«h·|§í¨î¬¡©ÊT²ÓM¹ï¸~½Fªº§K¬ÌºÊµø§@¥Î¡CPembrolizumab¬O¤@ºØ³æ®è§ÜÅé¡A·|»PPD-1µ²¦X¨ÃªýÂ_¨ä»PPD-L1¤ÎPD-L2ªº¥æ¤¬§@¥Î¡A¸Ñ°£¥ÑPD-1¸ô®|©Ò´C¤¶ªº§K¬Ì¤ÏÀ³ (¥]¬A§Ü¸~½F§K¬Ì¤ÏÀ³) §í¨î§@¥Î¡C¦b¦P·½¤p¹«¸~½F¼Ò«¬¸ÕÅ礤¡AªýÂ_PD-1ªº¬¡©Ê·|°§C¸~½F¥Íªø¡C
|
¾AÀ³¯g |
|
1.¶Â¦â¯À²ÓM½F ªvÀøµLªk¤Á°£©ÎÂಾ©Ê¶Â¦â¯À½F±wªÌ¡C 2.«D¤p²ÓMªÍÀù ³æ¿W¨Ï¥Î¡A¥Î©ó²Ä¤@½uªvÀø¸g½T®Ä¤§¸ÕÅçÀË´ú¥X¸~½F°ª«×ªí²{PD-L1 (tumor proportion score (TPS) ≥ 50%)ªºÂಾ«D¤p²ÓMªÍÀù±wªÌ¡A±wªÌ¤£¨ã¦³EGFR©ÎALK¸~½F°ò¦]²§±`ªÌ¡C »Ppemetrexed¤Îcarboplatin¨Ö¥Î¡A°µ¬°Âಾ©Ê¡A¤£¨ã¦³EGFR©ÎALK¸~½F°ò¦]²§±`¤§«DÅ쪬«D¤p²ÓMªÍÀùªº²Ä¤@½uªvÀøÃĪ«¡C 3.¨å«¬¦óªNª÷¤ó²O¤Ú½F ªvÀø¿©±w¹x©T©Ê©Î¥ý«e¦Ü¤Ö¤w±µ¨ü¤TºØªvÀø¤´´_µo¤§¨å«¬¦óªNª÷¤ó²O¤Ú½Fªº±wªÌ¡C 4.ÀYÀV³¡Å쪬²ÓMÀù ªvÀø¦b¨Ï¥Î§t¹`¤Æ¾ÇªvÀø´Á¶¡©ÎªvÀø«á¥X²{¯e¯f´c¤Æªº´_µo©ÎÂಾ©ÊÀYÀV³¡Å쪬²ÓMÀùªº±wªÌ¡C 5.ªc§¿¹D¤W¥ÖÀù ªvÀø±µ¨ü§t¹`¤Æ¾ÇªvÀø´Á¶¡©ÎªvÀø«á¥X²{¯e¯f´c¤Æ²{¶Hªº§½³¡±ß´Á©ÎÂಾ©Êªc§¿¹D¤W¥ÖÀù±wªÌ¡C 6. GÀù ªvÀø±w¦³´_µo©Ê§½³¡±ß´Á©ÎÂಾ©ÊG¸¢Àù©ÎG¹¹D±µ¦X³¡¸¢Àù¡A¸g½T®Ä©Ê¸ÕÅçÀË´ú¥X¸~½F¦³PD-L1ªí²{(ºî¦X¶§©Ê¤À¼Æ[Combined Positive Score, CPS]≥1)¡A¥B¥ý«e´¿¦b¨Ï¥Î¨âºØ(§t)¥H¤W¤§Àøªk(¥]¬A§t¦³fluoropyrimidine¤Î§t¹`¤Æ¾ÇÀøªk¡A¥H¤ÎHER2/neu¼Ð¹vÀøªk[¦pªG¾A¦X])ªvÀø®É©ÎªvÀø«á¥X²{¯e¯f´c¤Æ²{¶Hªº¯f¤H¡C
|
¥Îªk¥Î¶q |
|
¶Â¦â¯À½Fªº«Øij¾¯¶q KEYTRUDAªº«Øij¾¯¶q¬°2²@§J/¤½¤ç¡A¨C3¶g¤@¦¸¡A¨C¦¸¥HÀR¯ß¿éª`30¤ÀÄÁ¡Aª½¨ì¥X²{¯e¯f´c¤Æªº²{¶H©ÎµLªk±µ¨üªº¬r©Ê¤ÏÀ³¬°¤î¡C «D¤p²ÓMªÍÀùªº«Øij¾¯¶q KEYTRUDAªºµ¹ÃĤ覡¬°¨C3¶g¤@¦¸¡A¨C¦¸¥HÀR¯ß¿éª`30¤ÀÄÁ¡AY¥X²{¯e¯f´c¤Æ©Îµo¥ÍµLªk±µ¨ü¤§¬r©Ê¤ÏÀ³¡B©Î24Ó¤ë¨S¦³¥X²{¯e¯f´c¤Æ«h¤©¥H°±ÃÄ¡C ¨å«¬¦óªNª÷¤ó²O¤Ú½Fªº«Øij¾¯¶q KEYTRUDAªº«Øij¾¯¶q¬°200²@§J¡A¨C3¶g¤@¦¸¡A¨C¦¸¥HÀR¯ß¿éª`30¤ÀÄÁ¡AY¥X²{¯e¯f´c¤Æ©Îµo¥ÍµLªk±µ¨ü¤§¬r©Ê¤ÏÀ³¡B©Î24Ó¤ë¨S¦³¥X²{¯e¯f´c¤Æ«h¤©¥H°±ÃÄ¡C ÀYÀVÀùªº«Øij¾¯¶q KEYTRUDAªº«Øij¾¯¶q¬°200²@§J¡A¨C3¶g¤@¦¸¡A¨C¦¸¥HÀR¯ß¿éª`30¤ÀÄÁ¡AY¥X²{¯e¯f´c¤Æ¡Bµo¥ÍµLªk±µ¨ü¤§¬r©Ê¤ÏÀ³©Î24Ó¤ë¨S¦³¥X²{¯e¯f´c¤Æ«h¤©¥H°±ÃÄ¡C ªc§¿¹D¤W¥ÖÀùªº«Øij¾¯¶q KEYTRUDAªº«Øij¾¯¶q¬°200²@§J¡A¨C3¶g¤@¦¸¡A¨C¦¸¥HÀR¯ß¿éª`30¤ÀÄÁ¡AY¥X²{¯e¯f´c¤Æ©Îµo¥ÍµLªk±µ¨üªº¬r©Ê¤ÏÀ³¡B©Î24Ó¤ë¨S¦³¥XGÀùªº«Øij¾¯¶q KEYTRUDAªº«Øij¾¯¶q¬°200²@§J¡A¨C3¶g¤@¦¸¡A¨C¦¸¥HÀR¯ß¿éª`30¤ÀÄÁ¡AY¥X²{¯e¯f´c¤Æ¡Aµo¥ÍµLªk±µ¨ü¤§¬r©Ê¤ÏÀ³©Î24Ó¤ë¨S¦³¥X²{¯e¯f´c¤Æ«h¤©¥H°±ÃÄ¡C
|
ÃİʤO¾Ç |
|
éwª¬ºA¤À§GÅé¿n¤Î²×ºÝ¥b°I´Áªº´X¦ó¥§¡È[Åܲ§«Y¼Æ% (CV%)]¤À§O¬°6.0¤É(20%)¤Î22¤Ñ(32%)¡C ¥H¨C3¶g¤@¦¸ªº¤è¦¡«½Æ§ë¤©pembrolizumab¤§«á¡A¥i©ó16¶g¤º¹F¨ìéwª¬ºA¿@«×¡A¥þ¨»W¿n²v¬°2.1¿¡C¦b¨C3¶g¤@¦¸2¦Ü10²@§J/¤½¤çªº¾¯¶q½d³ò¤º¡Apembrolizumabªº¦y®p¿@«×(Cmax)¡B§C¨¦¿@«×(Cmin)¤Îéwª¬ºA¦å¤¤¿@«×®É¶¡¦±½u¤U±¿n(AUCss)³£·|¥H»P¾¯¶q¦¨¤ñ¨Òªº¼Ò¦¡¤É°ª¡C
|
°Æ§@¥Î |
|
¸¡Âm¡Bäú¤ß¤Î·kÄo¡C
|
¸T§Ò |
|
µL¡C
|
µ¹¥I³W©w |
|
9.69.§K¬ÌÀˬdÂIPD-1¡BPD-L1§í¨î¾¯(¦p pembrolizumab»s¾¯)¡G(108/4/1¡B108/6/1¡B109/4/1¡B109/6/1¡B109/11/1¡B110/5/1¡B110/10/1¡B111/4/1¡B111/6/1¡B112/8/1¡B112/10/1¡B112/12/1) 1. ¥»ÃþÃÄ«~±o©óÃÄ«~³\¥iÃÒµn¸ü¤§¾AÀ³¯g¤ÎÃÄ«~¥é³æ¤º¡A³æ¿W¨Ï¥Î©ó¤U¦C±wªÌ¡G (1)¶Â¦â¯À½F¡G¸~½FµLªk¤Á°£©ÎÂಾ¤§²Ä¤T´Á©Î²Ä¥|´Á¶Â¦â¯À½F¯f¤H¡A¥ý«e´¿±µ¨ü¹L¦Ü¤Ö¤@¦¸¥þ¨©ÊªvÀø¥¢±ÑªÌ¡C (2)«D¤p²ÓMªÍÀù¡G(109/4/1¡B109/11/1) I.¤£¾A¦X±µ¨ü¤Æ¾ÇªvÀø¤§Âಾ©Ê«D¤p²ÓMªÍÀù¦¨¤H±wªÌ¡A«DÅ쪬ÀùªÌ»Ý¬°EGFR/ALK/ROS-1¸~½F°ò¦]ì¥Í«¬¡BÅ쪬ÀùªÌ»Ý¬°EGFR/ALK¸~½F°ò¦]ì¥Í«¬¡A¥B¬Ò»Ý²Å¦X¤U¦C±ø¥ó¤§¤@¡G i.CTCAE(the common terminology criteria for adverse events) v4.0 grade¡Ù2 audiometric hearing loss ii.CTCAE v4.0 grade¡Ù2 peripheral neuropathy iii.CIRS(the cumulative illness rating scale) score >6 II.¥ý«e¤w¨Ï¥Î¹LplatinumÃþ¤Æ¾ÇªvÀø¥¢±Ñ«á¡A¤S¦³¯e¯f´c¤Æ¡A¥BEGFR/ALK¸~½F°ò¦]¬°ì¥Í«¬¤§±ß´ÁÅ쪬«D¤p²ÓMªÍÀù¦¨¤H±wªÌ¡C III.¥ý«e¤w¨Ï¥Î¹LplatinumÃþ¤Îdocetaxel/paclitaxelÃþ¤G½u(§t)¥H¤W¤Æ¾ÇªvÀø§¡¥¢±Ñ¡A¤S¦³¯e¯f´c¤Æ¡A¥BEGFR/ALK/ROS-1¸~½F°ò¦]¬°ì¥Í«¬¤§±ß´Á«D¤p²ÓMªÍ¸¢Àù¦¨¤H±wªÌ¡C (3)¨å«¬¦óªNª÷¤ó²O¤Ú½F¡G¥ý«e¤w±µ¨ü¦ÛÅé³y¦å·F²ÓM²¾´Ó(HSCT)»P²¾´Ó«ábrentuximab vedotin (BV)ªvÀø¡A¦ý¤S´_µo©Î´c¤Æªº¨å«¬¦óªNª÷¤ó²O¤Ú½F¦¨¤H±wªÌ¡C (4)ªc§¿¹D¤W¥ÖÀù¡G(109/11/1¡B112/10/1) I.¤£¾A¦X±µ¨ü¤Æ¾ÇªvÀø¤§Âಾ©Êªc§¿¹D¤W¥ÖÀù¦¨¤H±wªÌ¡A¥B»Ý²Å¦X¤U¦C±ø¥ó¤§¤@¡G i.CTCAE(the common terminology criteria for adverse events) v4.0 grade¡Ù2 audiometric hearing loss ii.CTCAE v4.0 grade¡Ù2 peripheral neuropathy iii.CIRS(the cumulative illness rating scale) score >6 II. ¥ý«e¤w¨Ï¥Î¹LplatinumÃþ¤Æ¾ÇªvÀø¥¢±Ñ«á¯e¯f´c¤Æªº§½³¡±ß´ÁµLªk¤Á°£©ÎÂಾ©Êªc§¿¹D¤W¥ÖÀù¦¨¤H±wªÌ¡C III.avelumab¥Î©ó±µ¨ü²Ä¤@½u§t¹`¤Æ¾ÇªvÀø4¦Ü6ÓÀøµ{«á¡A¯e¯f¥¼´c¤Æ¡A¥B¹F³¡¤À½w¸Ñ¡]PR¡^©Î¯e¯f§eéwª¬ºAªÌ(SD)¤§µLªk¤â³N¤Á°£§½³¡±ß´Á(stage ¢»)©ÎÂಾ©Êªc§¿¤W¥ÖÀù(stage ¢¼)¦¨¤H±wªÌ¤§ºû«ùÀøªk¡C(112/10/1¡^ (5)ÀYÀV³¡Å쪬²ÓMÀù(¤£§t»ó«|Àù)¡G(108/4/1¡B109/11/1¡B112/12/1) I.¥ý«e¥¼´¿±µ¨ü¥þ¨©ÊªvÀø¥BµLªk¤â³N¤Á°£¤§´_µo©Ê©ÎÂಾ©Ê(²Ä¤T´Á©Î²Ä¥|´Á)ÀYÀV³¡Å쪬²ÓMÀù¦¨¤H±wªÌ¡C¡]112/12/1) II.¥ý«e¤w¨Ï¥Î¹LplatinumÃþ¤Æ¾ÇªvÀø¥¢±Ñ«á¡A¤S¦³¯e¯f´c¤Æªº´_µo©Ê©ÎÂಾ©Ê(²Ä¤T´Á©Î²Ä¥|´Á)ÀYÀV³¡Å쪬²ÓMÀù¦¨¤H±wªÌ¡C(108/4/1¡B109/11/1¡B112/12/1¡^ III.¥»ÃþÃÄ«~»Pcetuximab¶È¯à¾Ü¤@¨Ï¥Î¡A¥BªvÀø¥¢±Ñ®É¤£¥i¤¬´«¡C (108/4/1¡^ (6)Âಾ©ÊGÀù¡G¥ý«e¤w¨Ï¥Î¹L¤G½u(§t)¥H¤W¤Æ¾ÇªvÀø§¡¥¢±Ñ¡A¤S¦³¯e¯f´c¤ÆªºÂಾ©ÊG¸¢Àù¦¨¤H±wªÌ¡A¥B©ó109¦~4¤ë1¤é«e¸g¼f®Ö¦P·N¥ÎÃÄ¡A«áÄòµû¦ô²Å¦XÄò¥Î¥Ó½Ð±ø¥óªÌ¡C(109/4/1) (7)±ß´ÁµÇ²ÓMÀù¡G¥ý«e¤w¨Ï¥Î¹L¦Ü¤Ö¤G½u¼Ð¹vÃĪ«ªvÀø§¡¥¢±Ñ¡A¤S¦³¯e¯f´c¤Æ¤§±ß´ÁµÇ²ÓMÀù¡A¨ä¯f²z¤W¬°«G²ÓMÀù(clear cell renal carcinoma)¤§¦¨¤H±wªÌ¡C (8)±ß´Á¨x²ÓMÀù¡G»Ý¦P®É²Å¦X¤U¦C©Ò¦³±ø¥ó¡G ¢¹.Child-Pugh A class¨x²ÓMÀù¦¨¤H±wªÌ¡C ¢º.¥ý«e¸gT.A.C.E.©ó12Ӥ뤺>=3¦¸§½³¡ªvÀø¥¢±ÑªÌ¡C ¢».¤w¨Ï¥Î¹L¦Ü¤Ö¤@½u¼Ð¹vÃĪ«ªvÀø¥¢±Ñ¡A¤S¦³¯e¯f´c¤ÆªÌ¡C¥»ÃþÃÄ«~»Pregorafenib¡Bramucirumab¶È¯à¾Ü¤@¨Ï¥Î¡A¥BªvÀø¥¢±Ñ®É¤£¥i¤¬´«¡C(108/6/1¡B110/5/1) ¢¼.¥¼´¿¶i¦æ¨xŦ²¾´Ó¡C ¢½.©ó109¦~4¤ë1¤é«e¸g¼f®Ö¦P·N¥ÎÃÄ¡A«áÄòµû¦ô²Å¦XÄò¥Î¥Ó½Ð±ø¥óªÌ¡C(109/4/1) (9)Àq§J²ÓMÀù¡Gavelumab¥Î©ó¥ý«e¤w¨Ï¥Î¹LplatinumÃþ¤Æ¾ÇªvÀø¥¢±Ñ«á¡A¤S¦³¯e¯f´c¤Æ¤§Âಾ©Ê²Ä¥|´ÁÀq§J²ÓMÀù(Merkel Cell Carcinoma)¤§¦¨¤H±wªÌ¡C(109/6/1) 2.¥»ÃþÃÄ«~±o©óÃÄ«~³\¥iÃÒµn¸ü¤§¾AÀ³¯g¤ÎÃÄ«~¥é³æ¤º¡A¨Ö¥Î¨ä¥LÃÄ«~©ó¤U¦C±wªÌ¡G(112/12/1) (1)±ß´Á¨x²ÓMÀù²Ä¤@½u¥ÎÃÄ(112/8/1¡B112/10/1): ¢¹.atezolizumab»Pbevacizumab¨Ö¥Î¡A¾A¥Î©óªvÀø¥¼´¿±µ¨ü¥þ¨©ÊÀøªk¤§Âಾ©Ê©ÎµLªk¤â³N¤Á°£¥B¤£¾A¦X§½³¡ªvÀø©Î§½³¡ªvÀø¥¢±Ñ¤§Child-Pugh A class±ß´Á¨x²ÓMÀù¦¨¤H±wªÌ¡A¨Ã²Å¦X¤U¦C±ø¥ó¤§¤@¡G¡]112/8/1¡B112/10/1) i.¨x¥~Âಾ¡]»·ºÝÂಾ©Î¨x¥~²O¤Úµ²«I¥Ç¡^¡C ii.¤j¦åºÞ«I¥Ç¡]¸~½F«I¥Ç¥DªùÀR¯ß©Î«I¥Ç¥ª/¥kÀR¯ß²Ä¤@©Î²Ä¤G¤À¤ä¡^¡C iii.¸g¾ÉºÞ°Ê¯ß¤Æ¾ÇÃĪ«®ê¶ëªvÀø¡]Transcatheter arterial chemo embolization, T.A.C.E.¡^¥¢±ÑªÌ¡A»Ý´£¨Ñ±wªÌ©ó12Ӥ뤺>=3¦¸§½³¡ªvÀø¤§¬ö¿ý¡C II.¶·±Æ°£¦³¥H¤U¥ô¤@±¡§Î¡G i.´¿±µ¨ü¾¹©x²¾´Ó¡C ii.¥¿¦b±µ¨ü§K¬Ì§í¨îÃĪ«ªvÀø¡C iii.¦³¤W®ø¤Æ¹D¥X¦å¤§ºÃ¼{¥B¥¼±µ¨ü§¹¥þªvÀø (¶·¦³¥b¦~¤º¤§¤ºµøÃèµû¦ô³ø§i)¡C III.»Psorafenib¡Blenvatinib¶È±o¾Ü¤@¨Ï¥Î¡A¤£±o¤¬´«¡C IV.atezolizumab»Pbevacizumab¨Ö¥ÎªvÀø¥¢±Ñ«á¡A¤£±o¥Ó½Ð¨Ï¥Îregorafenib©Îramucirumab¡C (2)pembrolizumab»Pcarboplatin¤Îpaclitaxel¨Ö¥Î°µ¬°Âಾ©ÊÅ쪬«D¤p²ÓMªÍÀùªº²Ä¤@½uªv療¡C(112/12/1) (3)¤p²ÓMªÍÀù¡Gatezolizumab»Pcarboplatin¤Îetoposide¨Ö¥Î¡A¾A¥Î©ó¥ý«e¥¼´¿±µ¨ü¤ÆÀø¡A¥BµL¸£³¡©ÎµL¯áÅèÂಾ¤§ÂX´²´Á(extensive stage)¤p²ÓMªÍÀù¦¨¤H±wªÌ¡C(112/12/1) 3.¨Ï¥Î±ø¥ó¡G (1) ¯f¤H¨Å骬ªp¨}¦n(ECOG¡Ø1)¡C (2) ¯f¤H¤§¤ßªÍ»P¨xµÇ¥\¯à¶·²Å¦X¤U¦C©Ò¦³±ø¥ó¡G I. NYHA(the New York Heart Association) Functional Class I©ÎII II.GOT<60U/L¤ÎGPT<60U/L¡A¥BT-bilirubin<1.5mg/dL (±ß´Á¨x²ÓMÀù¯f¤H¥i§K°£¦¹±ø¥ó) III.µÇ¥\¯à¡G(±ß´ÁµÇ²ÓMÀù¯f¤H¥i§K°£¦¹±ø¥ó) (109/4/1¡B112/10/1) iªc§¿¹D¤W¥ÖÀù²Ä¤@½u¥ÎÃÄ¡GeGFR>30mL/min/1.73m2¥B<60mL/min/1.73m2¡C ii.ªc§¿¹D¤W¥ÖÀù²Ä¤G½u¥ÎÃÄ¡GeGFR>30mL/min/1.73m2¡C iii.ªc§¿¹D¤W¥ÖÀùºû«ùªvÀø¡]112/10/1¡^¡GeGFR>30mL/min/1.73m2¡C iv.¨ä¥LÀù§O¡GCreatinine<1.5mg/dL¥BeGFR>60mL/min/1.73m2¡C (3)¯f¤H¤§¥Íª«¼Ð°Oªí²{¡G¨ÌÓ§OÃÄ«~¨Ï¥Î¨ä¹ïÀ³¤§²Ä¤Tµ¥¯ÅÅé¥~¶EÂ_ÂåÀø¾¹§÷(class III IVD)©ÒÀË´ú¤§PD-L1ªí²{¶q»Ý²Å¦X¤Uªí¡G(109/4/1¡B109/6/1¡B111/4/1¡B112/8/1¡B112/10/1¡B112/12/1) µ¹¥I½d³ò¡G ¶Â¦â¯À½F¡Apembrolizumab(Dako 22C3©ÎVentana SP263*)¡G¤£»ÝÀ˪þ³ø§i «D¤p²ÓMªÍÀù²Ä¤@½u¥ÎÃÄ¡Apembrolizumab(Dako 22C3©ÎVentana SP263*)¡GTC¡Ù50% «D¤p²ÓMªÍÀù²Ä¤G½u¥ÎÃÄ¡Apembrolizumab(Dako 22C3©ÎVentana SP263*)¡GTC¡Ù50% «D¤p²ÓMªÍÀù²Ä¤T½u¥ÎÃÄ¡Apembrolizumab(Dako 22C3©ÎVentana SP263*)¡GTC¡Ù50% Å쪬«D¤p²ÓMªÍÀù²Ä¤@½u¥ÎÃÄ(¨Ö¥Î¤ÆÀø)¡Apembrolizumab(Dako 22C3©ÎVentana SP263*):TPS 1~49% ¨å«¬¦óªNª÷¤ó²O¤Ú½F¡Apembrolizumab(Dako 22C3©ÎVentana SP263*)¡G¤£»ÝÀ˪þ³ø§i ªc§¿¹D¤W¥ÖÀù²Ä¤@½u¥ÎÃÄ¡Apembrolizumab(Dako 22C3©ÎVentana SP263*)¡GCPS¡Ù10 ªc§¿¹D¤W¥ÖÀù²Ä¤G½u¥ÎÃÄ¡Apembrolizumab(Dako 22C3©ÎVentana SP263*)¡GCPS¡Ù10 ªc§¿¹D¤W¥ÖÀùºû«ùÀøªk¡Apembrolizumab(Dako 22C3©ÎVentana SP263*)¡G¥»ÃÄ«~©|¥¼µ¹¥I©ó¦¹¾AÀ³¯g ÀYÀV³¡Å쪬²ÓMÀù²Ä¤@½u¥ÎÃÄ¡Apembrolizumab(Dako 22C3©ÎVentana SP263*)¡GCPS¡Ù20 ÀYÀV³¡Å쪬²ÓMÀù²Ä¤G½u¥ÎÃÄ¡Apembrolizumab(Dako 22C3©ÎVentana SP263*)¡GTPS¡Ù50% GÀù¡Apembrolizumab(Dako 22C3©ÎVentana SP263*)¡GCPS¡Ù1 ±ß´ÁµÇ²ÓMÀù¡Apembrolizumab(Dako 22C3©ÎVentana SP263*)¡G¥»ÃÄ«~©|¥¼µ¹¥I©ó¦¹¾AÀ³¯g¡C ±ß´Á¨x²ÓMÀù¡Apembrolizumab(Dako 22C3©ÎVentana SP263*)¡G¥»ÃÄ«~©|¥¼µ¹¥I©ó¦¹¾AÀ³¯g¡C ±ß´Á¨x²ÓMÀù²Ä¤@½u¥ÎÃÄ(¨Ö¥Îbevacizumab)¡Apembrolizumab(Dako 22C3©ÎVentana SP263*)¡G¥»ÃÄ«~©|¥¼µ¹¥I©ó¦¹¾AÀ³¯g¡C Àq§J²ÓMÀù¡Apembrolizumab(Dako 22C3©ÎVentana SP263*)¡G¥»ÃÄ«~©|¥¼µ¹¥I©ó¦¹¾AÀ³¯g¡C ¤p²ÓMªÍÀù(¨Ö¥Î¤ÆÀø)¡Apembrolizumab(Dako 22C3©ÎVentana SP263*)¡G¥»ÃÄ«~©|¥¼µ¹¥I©ó¦¹¾AÀ³¯g¡C (4)¨C¦ì¯f¤H¨CÓ¾AÀ³¯gµ¹¥I¤@ºØ§K¬ÌÀˬdÂI§í¨î¾¯¥B¤£±o¤¬´«¡AªvÀø´Á¶¡¥ç¤£¥i¦X¨Ö¥Ó³ø¸Ó¾AÀ³¯g¤§¼Ð¹vÃĪ«¡]atezolizumab»Pbevacizumab¨Ö¥Î©ó±ß´Á¨x²ÓMÀù²Ä¤@½u¥ÎÃÄ°£¥~¡^¡AµL®Ä«á©Îµ¹¥I®Éµ{´Áº¡«á«h¤£¦Aµ¹¥I¸Ó¾AÀ³¯g¬ÛÃö¤§¼Ð¹vÃĪ«¡C(108/4/1¡B111/6/1¡B112/8/1) (5)µ¹¥I®Éµ{´Á¡G¦Ûªì¦¸³B¤è¥ÎÃĤé°_ºâ2¦~¡C(109/4/1¡B109/11/1) (6)»Ý¸g³æµ§¹q¤l¥Ó½Ð¨Æ«e¼f¬d®Öã«á¨Ï¥Î¡A¥Ó½Ð®É»Ý¤W¶Ç¯f¾ú¸ê®Æ(¤£¾A¥Î¯S®í¯f¨Ò¨Æ«e¼f¬d¡A¥ç¤£¾A¥Îºò«æ³ø³Æ¡A±©¤wÀò®Ö©w¥ÎÃĤ§¯f¤H¦]Âà°|¥iºò«æ³ø³Æ¥Ó½ÐÄò¥Î)¡C(108/4/1¡B110/10/1¡B111/6/1) (7)¨C¦¸¥Ó½Ð¥H12¶g¬°¡Aªì¦¸¥Ó½Ð®É»ÝÀ˪þ¥H¤U¸ê®Æ¡G(108/6/1¡B109/11/1¡B111/6/1) I.½T¹ê±w¦³¬ÛÃöÀù¯g¤§¯f²z©Î²ÓMÀˬd³ø§i¡A¶Â¦â¯À½F±wªÌ»Ý¥tÀ˪þBRAF¸~½F°ò¦]ÀË´úµ²ªG¡B«D¤p²ÓMªÍÀù±wªÌ»Ý¥tÀ˪þ²Å¦Xµ¹¥I¾AÀ³¯g¤º®e³W©w¤§¸~½F°ò¦]ÀË´úµ²ªG¡C ¢º.¥Íª«¼Ð°Oªí²{¶qÀË´ú³ø§i¡G²Å¦X¥»«OÀIÂåÀøªA°Èµ¹¥I¶µ¥Ø¤Î¤ä¥I¼Ð·Ç¦ñÀH¦¡¶EÂ_½s¸¹30103B³W©w¤§¨ÌÓ§OÃÄ«~¨Ï¥Î¨ä¹ïÀ³¤§²Ä¤Tµ¥¯ÅÅé¥~¶EÂ_ÂåÀø¾¹§÷(class ¢» IVD)©ÒÀË´ú¤§PD-L1ªí²{¶qÀË´úµ²ªG¡A¨Ã¥Ñ¯f²z±M¬ìÂå®vñµo³ø§i¡C(111/6/1) ¢».¯f¤H¨Å骬ªp¨}¦n(ECOG¡Ø1)¤Î¤ßªÍ»P¨xµÇ¥\¯à¤§µû¦ô¸ê®Æ¡C IV.¯f¤H12¶g¤º¤§¯e¯f¼v¹³Àˬd¤Î³ø§i(¦p¯Ý³¡X¥ú¡B¹q¸£Â_¼h©Î¨ä¥L¥i§@¬°µû¦ôªº¼v¹³)¡A¦¹¼v¹³ÃÒ©ú¥H¥i´ú¶q(measurable)ªº¯f¨_¬°Àu¥ý¡A¦p¨S¦³¥i¥H´ú¶qªº¯f¨_¡A«h¥iµû¦ô(evaluable)ªº¯f¨_¥ç¥i±Ä¥Î¡C ³Æµù¡G¤Wz¼v¹³Àˬd¤§µ¹¥I½d³ò¤£¥]¬A¥¿¤l³y¼v(PET)¡C V.¥ý«e¤w±µ¨ü¹L¤§ªvÀø»P§¹¾ã¥ÎÃĸê®Æ(¦p¤Æ¾ÇªvÀø¡B¼Ð¹vÃĪ«¤Î¦Û¶Oµ¥¥ÎÃĤ§¾¯¶q¤ÎÀøµ{)¤Î¨äªvÀøµ²ªG¡F¨å«¬¦óªNª÷¤ó²O¤Ú½F±wªÌ»Ý¥tÀ˪þ¦ÛÅé³y¦å·F²ÓM²¾´Ó¤§¯f¾ú¬ö¿ý¡F¨x²ÓMÀù±wªÌ»Ý¥tÀ˪þT.A.C.E.ªvÀø¬ö¿ý¡C VI.¨Ï¥Î§K¬ÌÀˬdÂI§í¨î¾¯¤§ªvÀøpµe(treatment protocol)¡C ¢¿.¨Ï¥Î©ó«D¤p²ÓMªÍÀù¤Îªc§¿¹D¤W¥ÖÀù²Ä¤@½u¥ÎÃĮɡA¶·¥tÀ˪þ¤U¦C¨ä¤¤¤@¶µ¦õÃÒ¸ê®Æ¡G i.CTCAE(the common terminology criteria for adverse events) v4.0 grade¡Ù2 audiometric hearing loss ⅱ.CTCAE v4.0 grade¡Ù2 peripheral neuropathy ⅲ.CIRS(the cumulative illness rating scale) score >6 ¢À.¨ä¥L¦õÃÒ¯f¾ú¸ê®Æ¡C (8)¥ÎÃÄ«á¨C12¶g¦Ü¤Öµû¦ô¤@¦¸¡A¥Hi-RECIST¼Ð·Ç(HCC±wªÌ¥HmRECIST¼Ð·Ç)µû©wÃĪ«Àø®Ä¤ÏÀ³¡A¨Ì¤U¦Cì«h¥Ó½ÐÄò¥Î¡G(109/4/1¡B109/11/1) I.¦³Àø®Ä¤ÏÀ³(PR¤ÎCR)ªÌ±oÄ~Äò¥ÎÃÄ¡F II.¥X²{¯e¯f´c¤Æ(PD)©Î¥X²{¤¤¡B««×©Î¦M¤Î¥Í©R¤§ÃĪ«¤£¨}¤ÏÀ³ªÌ¡AÀ³°±¤î¥ÎÃÄ¡F ¢».¥X²{¯e¯f¨Öµo¯g©Î»´«×ÃĪ«¤£¨}¤ÏÀ³µ¥¡A¼È°±¥ÎÃĶW¹Lì¨Æ«e¼f¬d®Ö©w¤é°_24¶g´ÁªÌ¡A¤£±o¥Ó½ÐÄò¥Î¡C IV.¥ÎÃÄ«áµû¦ô¯e¯f§eéwª¬ºAªÌ(SD)¡A¥i«ùÄò¦A¥ÎÃÄ12¶g¡A¨Ã©ó12¶g«á¦A¦¸µû¦ô¡F¸g³sÄò¤G¦¸µû¦ô¬Ò¬°SDªÌ¡A¤£±o¥Ó½ÐÄò¥Î¡C (9)¥Ó½ÐÄò¥Î®É¡A»ÝÀ˪þ¯f¤H12¶g¤º¤§µû¦ô¸ê®Æ¦p¤U¡G(108/6/1¡B109/11/1) I.¯f¤H¨Å骬ªp¨}¦n(ECOG¡Ø1)¤Î¤ßªÍ»P¨xµÇ¥\¯à¤§µû¦ô¸ê®Æ¡C II.¥Hi-RECIST¼Ð·Ç(HCC±wªÌ¥HmRECIST¼Ð·Ç)µû©w¤§ÃĪ«Àø®Ä¤ÏÀ³(PR¡BCR¡BSD)¸ê®Æ¡B¼v¹³Àˬd¤Î³ø§i(¦p¯Ý³¡X¥ú¡B¹q¸£Â_¼h©Î¨ä¥L¥i§@¬°µû¦ôªº¼v¹³)¡A¦¹¼v¹³ÃÒ©ú¥H¥i´ú¶q(measurable)ªº¯f¨_¬°Àu¥ý¡A¦p¨S¦³¥i¥H´ú¶qªº¯f¨_¡A«h¥iµû¦ô(evaluable)ªº¯f¨_¥ç¥i±Ä¥Î¡C ³Æµù¡G¤Wz¼v¹³Àˬd¤§µ¹¥I½d³ò¤£¥]¬A¥¿¤l³y¼v(PET)¡C ¢».¨Ï¥Î©ó«D¤p²ÓMªÍÀù¤Îªc§¿¹D¤W¥ÖÀù²Ä¤@½u¥ÎÃĮɡA¶·¥tÀ˪þ¤U¦C¨ä¤¤¤@¶µ¦õÃÒ¸ê®Æ¡G i.CTCAE(the common terminology criteria for adverse events) v4.0 grade¡Ù2 audiometric hearing loss ⅱ.CTCAE v4.0 grade¡Ù2 peripheral neuropathy ⅲ.CIRS(the cumulative illness rating scale) score >6 IV.¨ä¥L¦õÃÒ¯f¾ú¸ê®Æ¡C 4.µn¿ý»Pµ²®×§@·~¡G(109/11/1¡^ (1)Âå®v³B¤è¨Ï¥Î¥»ÃþÃÄ«~¶·°t¦X¨Ìµn¿ý¯f¤H¨Å骬ªp¡B¥Íª«¼Ð°O(PD-L1)ÀË´ú¡B¯f±¡µo®i¡BÃÄ«~¨Ï¥Î¦¨®Ä»P°Æ§@¥Îµ¥¸ê®Æ¡C (2)¯f¤HÕµ²§ôªvÀø¡B°±¤î¥ÎÃÄ¡B¥¼³q¹LÄò¥Î¥Ó½Ð¡B¼È°±¥ÎÃĶW¹Lì¨Æ«e¼f¬d®Ö©w¤é°_24¶g´Á©Î¹Fµ¹¥I®Éµ{´Á®É¡AÂå¨Æ¾÷ºc¶·¦b28¤Ñ¤º©óVPN¨t²Îµn¿ýµ²®×¡C¹O´Á¥¼µn¿ýµ²®×ªÌ¡A¨t²Î¦Û°Êµ²®×¡A¥B¤£¤©¤ä¥I¸ÓӮצ۫e¦¸¨Æ«e¼f¬d®Ö©w¤é«á¥Ó³ø¤§ÃĶO¡C (3)¤wµ²®×ªÌ¦Ûµ²®×¤é«á¤£¤©¤ä¥IÃĶO¡C
|
ĵ»y |
|
¯f±w¦b±µ¨üKEYTRUDAªvÀø«á¥i¯à·|¥X²{§K¬Ì´C¤¶©Ê¤£¨}¤ÏÀ³¡A¥]§tÄY«©ÎP¦º©Êªº®×¨Ò¡CªvÀø¹Lµ{©Î°±¤îªvÀø«á¬Ò¦³¥i¯àµo¥Í§K¬Ì´C¤¶©Ê¤£¨}¤ÏÀ³¡C
|
¹L¶q³B²z |
|
¥Ø«e¨ÃµL¥ô¦óKEYTRUDA¨Ï¥Î¹L¶qªº¸ê°T¡C
|
ÃÄ«~«O¦s¤è¦¡ |
|
µ}ÄÀ«áªºKEYTRUDA·»²G¥i¦s©ñ©ó¡G «Ç·ÅÀô¹Ò¤£¥i¶W¹L6¤p®É¡C³o¥]¬A©ó«Ç·Å¤U¡AIV³U¤¤¤§¿éª`·»²Gªº¦s©ñ®É¶¡¡B¥H¤Î¿éª`©Ò»Ýnªº®É¶¡¡C 2¢XC¦Ü8¢XC (36¢XF¦Ü46¢XF)ªº§NÂÃÀô¹Ò¤£¥i¶W¹L24¤p®É¡C¦pªG¬O§NÂæs©ñ¡A§ëÃÄ«eÀ³¥ýÅýµ}ÄÀ«áªº·»²G¦^´_¦Ü«Ç·Å¡C
|